Ninepoint Partners’s Genmab GMAB Stock Holding History

Ninepoint Partners’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-67	Closed	-$2.06K	–	167
2025 Q4	$2.06K	Buy	+67	New	+$2.09K	﹤0.01%	156

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Ninepoint Partners's GMAB Position: Q1 2026 in Review

Ninepoint Partners sold out of Genmab (GMAB) in Q1 2026, closing a stake of 67 shares — an estimated $2.06K sold.

Ninepoint Partners first reported a position in GMAB in Q4 2025 and held it in 1 quarter. The position peaked at $2.06K in Q4 2025. 274 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Ninepoint Partners reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
Ninepoint Partners sold 67 Genmab shares in Q1 2026, an estimated $2.06K.
Ninepoint Partners first reported a position in Genmab in Q4 2025 and held it in 1 quarter.
Ninepoint Partners's Genmab position peaked at $2.06K in Q4 2025.
274 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Ninepoint Partners's 13F filing for Q1 2026, filed 11 Aug 2026.